NASDAQ · ALGS
Aligos Therapeutics, Inc.
Healthcare · Biotechnology
$5.51▼ 0.72% ($0.04)at close
After hours$5.40▼ 2.00%7:30 PM ET
Market cap
Valuation
Revenue & margin DCF
Verdict: fairly priced. Price between Bear and Base.
The price needs 19.1% revenue growth a year for 10 years. Our scenarios assume 14.1–24.4%.
Its past 4 years averaged −15.8% a year.
Value per share
Base case
$6.07
Price used $5.51 is 9% below this
USD · TTM ending Jun 30, 2026 · Price Sep 25, 8:00 PM UTC
Revenue each value needs
Revenue today $31.5M. The price needs $180M by 2036. Base case: $189M. At its recent pace: $5.6M. Bear to Bull: $117M to $280M.
Revenue today $31.5M. The price needs $180M by 2036. Base case: $189M. At its recent pace: $5.6M. Bear to Bull: $117M to $280M.
Revenue in 2036
today $31.5M
−$8.5Mless than the Base case
Value per share · Base case
$6.07
Price $5.51
9% below this
- 10-yr revenue CAGR
- 19.6%
- Ending operating margin
- 0.0%
- Discount rate
- 18.0%
USD · TTM ending Jun 30, 2026 · Price Sep 25, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 41.13% over the last year. Revenue grew 893.01% over the trailing twelve months. Operating margin moved from -2,473.35% to -250.63%. Free cash flow declined 25.82% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.
What would invalidate this read
This read changes if operating margin (currently -250.63%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Return analysis
Company profile
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases.
Market multiples
Stock splits
Every 25 shares became 1
Profitability & growth
Analyst consensus
3
Buy
2
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 5, 2026
Q4 FY26 · EPS est -$2.44 · Revenue est $4.85M
View
Institutional Sentiment
Aligos Therapeutics, Inc. · ALGS
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.